IVIG Privigen denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for ivig privigen are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Privigen (IVIG) on a "Not FDA-Approved" Basis

This denial type for Privigen (immune globulin intravenous, human — 10%) is almost always an indication-based denial rather than a product-level one. Privigen itself is an FDA-licensed biological product with established approved indications. When Humana uses "not FDA-approved" language, it typically means the specific condition for which your physician prescribed Privigen is not among the labeled indications recognized in the FDA prescribing information — an "off-label" use in regulatory terms. Off-label prescribing is legal and common in clinical medicine; however, insurers are not automatically required to cover it, and the denial often signals that the indication must be justified through additional channels.

## Why This Denial Is Appealable

Off-label use of FDA-approved biologics is routinely covered by health plans when supported by recognized compendia (such as the DrugDEX/Micromedex, Clinical Pharmacology, or NCCN Drugs & Biologics Compendium listings) or by the applicable professional-society guideline. Many states require insurers to cover compendia-listed off-label uses. Even where compendia listings are absent, a prescribing specialist can argue the use is supported by the current standard of care and that Humana's denial is inconsistent with generally accepted medical practice. The key is to reframe the appeal around medical necessity and guideline support rather than FDA-label status alone.

## Your Federal Appeal Rights

• Internal appeal: ACA §2719 and ERISA §503 require a full-and-fair internal review. File within the deadline on your denial notice.
• External review: After an adverse internal determination, an IRO evaluates whether the denial was consistent with generally accepted standards of medical practice. The external-review window is typically around four months. Expedited review is available when delay would seriously jeopardize health.

## Concrete Appeal Steps and Timeline

1. Confirm the exact indication: document in the appeal the precise diagnosis for which Privigen is prescribed, with ICD code and clinical context. 2. Ask your prescribing specialist to identify whether the indication appears in a recognized drug compendia — if it does, cite the compendium by name in the appeal letter. 3. Have the specialist write a medical-necessity letter referencing the applicable professional-society guideline and explaining how off-label use is the standard of care for this indication. 4. Submit the internal appeal. Standard pre-service appeals: Humana must respond within 30 days. 5. If denied, request external review immediately — IROs specifically assess whether off-label uses are consistent with standard practice.

## Documentation to Gather

• Diagnosis records with the specific indication clearly documented
• Prescriber letter citing the applicable guideline organization and any drug compendia that list the off-label use
• Clinical severity and prior-treatment history records
• Any peer-reviewed references your prescriber identifies in support of the off-label use (use only what your physician provides; do not fabricate citations)

## Criteria-Mapping Structure

Obtain Humana's medical policy for IVIG and any coverage criteria for off-label biologics. List each criterion. For each, document either (a) that the FDA label does cover the indication, with label citation, or (b) that an applicable compendia or guideline supports the use, paired with the chart evidence that places your case within that guideline's scope.